NEISSERIA MENINGITIDES B, RECOMBINANT, COMPONENT, ADSORBED Q.S.
|
|
|
- Ashlynn Wilcox
- 10 years ago
- Views:
Transcription
1 Final Belgian list: (Last update 02/12/2013) marketing name Active substance MAH Reason on list ADCETRIS BRENTUXIMAB VEDOTINE TAKEDA GLOBAL R&D CENTRE (EUROPE) LTD, Cond Auth, ALDURAZYME LARONIDASE GENZYME EUROPE B.V. Auth under excep circumstances, AMYVID FORBETAPIR (F-18) Q.S. ELI LILLY NEDERLAND BV ARZERRA OFATUMUMAB MG/ML GLAXO GROUP LTD Conditional auth, ATRIANCE NELARABINE 5.00 MG/ML GLAXO GROUP LTD Auth under excep circumstances ATRYN ANTITHROMBIN ALFA GTC BIOTHERAPEUTICS UK LIMITED Auth under excep circumstances, AUBAGIO TERIFLUNOMIDE SANOFI-AVENTIS GROUPE BENLYSTA BELIMUMAB GLAXO GROUP LTD BETMIGA MIRABEGRON ASTELLAS PHARMA EUROPE B.V. BEXSERO NEISSERIA MENINGITIDES B, RECOMBINANT, COMPONENT, ADSORBED Q.S. NOVARTIS VACCINES & DIAGNOSTICS S.R.L. BINDREN COLESTILAN NOVARTIS VACCINES & DIAGNOSTICS S.R.L. BOSULIF BOSUTINIB (MONOHYDRATE) MG PFIZER LIMITED, Cond Auth, BRETARIS GENUAIR ACLIDINIUM (BROMURE) ALMIRALL S.A, CAPRELSA VANDETANIB ASTRAZENECA AB, Cond Auth CEPLENE HISTAMINE DIHYDROCHLORIDE MEDA AB Auth under excep circumstances CHAMPIX VARENICLINE (TARTRATE) PFIZER LIMITED CHLOE MITHRA PHARMACEUTICALS S.A. CINRYZE C1-INHIBITOR IU VIROPHARMA BVBA CLAUDIA - 35 SANDOZ N.V. CLEVIPREX CLEVIDIPINE BUTYRATE THE MEDICINES COMPANY UK LTD CONSTELLA LINACLOTIDE ALMIRALL S.A CUPRYMINA COPPER (64-CU) CHLORIDE Q.S. SPARKLE S.R.L DACOGEN DECITABINE JANSSEN-CILAG INTERNATIONAL NV DALIRESP ROFLUMILAST MCG NYCOMED GMBH DAPHNE MITHRA PHARMACEUTICALS S.A. DAXAS ROFLUMILAST NYCOMED GMBH DEFITELIO DEFIBROTIDE??? New biological, authorised under exceptional circumstances DIACOMIT STIRIPENTOL BIOCODEX Conditional auth DIANE-35 BAYER N.V.
2 DIFICLIR FIDAXOMICIN ASTELLAS PHARMA EUROPE B.V. EDARBI AZILSARTAN MEDOXOMIL (POTASSIUM) TAKEDA GLOBAL R&D CENTRE (EUROPE) LTD EDURANT RILPIVIRINE (HYDROCHLORIDE) JANSSEN-CILAG INTERNATIONAL NV EKISTOL CILOSTAZOL??? Outcome Referral Art 31, EKLIRA GENUAIR ACLIDINIUM (BROMURE) ALMIRALL S.A., ELAPRASE IDURSULFASE SHIRE HUMAN GENETIC THERAPIES AB Auth under excep circumstances ELIQUIS APIXABAN BRISTOL MYERS SQUIBB/PFIZER EEIG ELISAMYLAN 35 MYLAN BVBA/SPRL ELVANSE / TYVENSE LISDEXAMPHETAMINE BRYSTOL MYERS SQUIBB/ PFIZER EEIG ENUREV BREEZHALER GLYCOPYRRONIUM (BROMIDE) NOVARTIS EUROPHARM LIMITED, ERIVEDGE VISMODEGIB ROCHE REGISTRATION LIMITED, Cond Auth ESBRIET PIRFENIDONE INTERMUNE EUROPE LTD, EURARTESIM PIPERAQUINE TETRAPHOSPHATE (TETRAHYDRATE), DIHYDROARTEMISININ (DHA) SIGMA-TAU INDUSTRIE FARMAC. RIUNITE SPA, EVARREST FIBRINOGEN, HUMAN Q.S., THROMBIN, HUMAN Q.S. OMRIX BIOPHARMACEUTICALS N.V. EVIPLERA ENOFOVIR DISOPROXIL (FUMARATE), EMTRICITABINE, RILPIVIRINE (HYDROCHLORIDE) GILEAD SCIENCES LTD EVOLTRA CLOFARABINE GENZYME EUROPE B.V. Auth under excep circumstances EXJADE DEFERASIROX NOVARTIS EUROPHARM LIMITED EYLEA AFLIBERCEPT BAYER AG FAMPYRA FAMPRIDINE BIOGEN IDEC LTD, Cond Auth FIRDAPSE AMIFAMPRIDINE (PHOSPHATE) BIOMARIN EUROPE LTD Auth under excep circumstances, FLUENZ INFLUENZA VIRUS, LIVE, ATTENUATED Q.S. MEDIMMUNE LLC FORXIGA DAPAGLIFLOZIN (PROPANEDIOL MONOHYDRATE) BRISTOL MYERS SQUIBB/ASTRAZENECA EEIG FYCOMPA PERAMPANEL EISAI EUROPE LTD GILENYA FINGOLIMOD (HYDROCHLORIDE) 0.50 MG NOVARTIS EUROPHARM LIMITED, GIOTRIF AFATINIB??? GLYBERA ALIPOGENE TIPARVOVEC Q.S. UNIQURE BIOPHARMA B.V, Auth under excep circumstances, GRASTOFIL FILGASTRIM??? GRATIELLA 35 3DDD PHARMA N.V. HALAVEN ERIBULIN (MESYLATE) 0.44 MG/ML EISAI LIMITED
3 HEXACIMA HEXYON Diphtheria, tetanus, pertussis (acellular, component), hepatitis B (rdna), poliomyelitis (inactivated) and Haemophilus influenzae type B conjugate vaccine (adsorbed) Diphtheria, tetanus, pertussis (acellular, component), hepatitis B (rdna), poliomyelitis (inactivated) and Haemophilus influenzae type B conjugate vaccine (adsorbed) SANOFI PASTEUR SA SANOFI PASTEUR MSD HIZENTRA IMMUNOGLOBULIN HUMAN NORMAL MG/ML BIOCLS GMBH HYQVIA IMMUNOGLOBULIN HUMAN NORMAL MG/ML BAXTER INNOVATIONS GMBH ICLUSIG PONATINIB (HYDROCHLORIDE) ARIAD PHARMA LTD ILARIS CANAKINUMAB NOVARTIS EUROPHARM LIMITED Auth under excep circumstances, IMVANEX Modified Vaccinia Ankara virus - Bavarian Nordic (MVA-BN) live virus BAVARIAN NORDIC A/S INCIVO TELAPREVIR JANSSEN-CILAG INTERNATIONAL NV, Auth under excep circumstances INCRELEX MECASERMIN IPSEN PHARMA Auth under excep circumstances, INCRESYNC Alogliptin/pioglitazone??? INFLECTRA NFLIXIMAB HOSPIRA UK LTD INFLUSPLIT TETRA Influenza virus inactivated split virion GLAXO GROUP LTD Biological INLYTA AXITINIB PFIZER LIMITED INTELENCE ETRAVIRINE JANSSEN-CILAG INTERNATIONAL NV Conditional auth INVIRASE SAQUINAVIR (MESILATE) ROCHE REGISTRATION LIMITED INVOKANA Canagliflozin Janssen-Cilag International N.V. IPREZIV AZILSARTAN MEDOXOMIL (POTASSIUM) TAKEDA GLOBAL R&D CENTRE (EUROPE) LTD JAKAVI RUXOLITINIB (PHOSPHATE) NOVARTIS EUROPHARM LIMITED, JAYDESS LEVONORGESTREL MG BAYER N.V. JENTADUETO METFORMIN HYDROCHLORIDE, LINAGLIPTIN BOEHRINGER INGELHEIM INTERNATIONAL GMBH JETREA OCRIPLASMIN THROMBOGENICS NV JEVTANA CABAZITAXEL SANOFI-AVENTIS GROUPE KADCYLA Trastuzumab emtansine Roche Registration Ltd KALYDECO IVACAFTOR VERTEX PHARMACEUTICALS LIMIT, KRYSTEXXA PEGLOTICASE SAVIENT PHARMA IRELAND LIMITED, LACTEST GASILOXE Lactest S.L. / Venter Pharma S.L. LEMTRADA ALEMTUZUMAB GENZYME THERAPEUTICS LTD
4 LIBERTEK ROFLUMILAST NYCOMED GMBH LOJUXTA LOMITAPIDE (MESYLATE) AEGERION PHARMACEUTICALS, Auth under excep circumstances LONQUEX LIPEGFILGRASTIM TEVA PHARMA BV, LYXUMIA LIXISENATIDE SANOFI-AVENTIS GROUPE MACI CHONDROCYTES, AUTOLOGOUS CULTURED Q.S. GENZYME EUROPE B.V. NAGLAZYME GALSULFASE BIOMARIN EUROPE LTD Auth under excep circumstances, NEXOBRID PROTEOLYTIC ENZYMES (CONCENTRATE) ENRICHED IN BROMELAIN TEVA PHARMA GMBH, NIMENRIX NEISSERIA MENINGITIDES A+C+W+Y, POLYSACCHARIDE CONJ. TO TETANUS TOXOID Q.S. GLAXOSMITHKLINE BIOLOGICALS S.A., NOVOEIGHT Turoctocog alfa NOVO NORDISK A/S NOVOTHIRTEEN CATRIDECACOG NOVO NORDISK A/S NULOJIX BELATACEPT BRISTOL-MYERS SQUIBB PHARMA EEIG OPGENRA EPTOTERMIN ALFA OLYMPUS BIOTECH LTD OPTIMARK GADOVERSETAMIDE MALLINCKRODT MEDICAL GMBH ORPHACOL CHOLIC ACID LABORATOIRES CTRS Auth under excep circumstances OSSEOR STRONTIUM RANELATE SERVIER, LES LABORATOIRES OVALEAP FOLLITROPIN ALPHA??? PANDEMRIX INFLUENZA VIRUS (INACTIVATED) Q.S. GLAXOSMITHKLINE BIOLOGICALS S.A. PERJETA PERTUZUMAB ROCHE REGISTRATION LIMITED PICATO INGENOL MEBUTATE LEO PHARMA A/S PIXUVRI PIXANTRONE (DIMALEATE) CTI LIFE SCIENCES LTD, Cond Auth PLETAL CILOSTAZOL??? Outcome Referral Art 31, POMALIDOMIDE CELGENE POMALIDOMIDE CELGENE EUROPE LIMITED, PRIALT ZICONOTIDE (ACETATE) EISAI LIMITED Auth under excep circumstances, PROTELOS STRONTIUM RANELATE SERVIER, LES LABORATOIRES PROVENGE AUTOLOGOUS PERIPHERAL BLOOD MONONUCLEAR CELLS ACTIVATED WITH PAP-GM-CS Q.S. DENDREON UK LIMITED, RELVAR ELLIPTA Fluticasone furoate/vilanterol trifenatate Glaxo Group Ltd, REMSIMA INFLIXIMAB CELLTRION HEALTHCARE HUNGARY KFT. REPLAGAL AGALSIDASE ALFA SHIRE HUMAN GENETIC THERAPIES AB Auth under excep circumstances, REVESTIVE TEDUGLUTIDE NYCOMED DANMARK APS,
5 RIENSO FERUMOXYTOL TAKEDA PHARMA A/S RYZODEG INSULIN ASPART UML, INSULIN DEGLUDEC UML NOVO NORDISK A/S SEEBRI BREEZHALER GLYCOPYRRONIUM (BROMIDE) NOVARTIS EUROPHARM LIMITED, SELINCRO NALMEFENE (HYDROCHLORIDE DIHYDRATE) LUNDBECK A/S SIGNIFOR PASIREOTIDE (DIASPARTATE) NOVARTIS EUROPHARM LIMITED SOMATROPIN BIOPARTNERS SOMATROPIN BIOPARTNERS SPEDRA AVANAFIL VIVUS BV STIVARGA REGORAFENIB BAYER AG STRIBILD TENOFOVIR DISOPROXIL (FUMARATE), EMTRICITABINE, ELVITEGRAVIR, COBICISTAT GILEAD SCIENCES LTD TAFINLAR DABRAFENIB GLAXOSMITHKLINE TRADING SERVICES LIMITED TEYSUNO TEGAFUR, GIMERACIL, OTERACIL (MONOPOTASSIUM) NORDIC GROUP BV, TOVANOR BREEZHALER GLYCOPYRRONIUM (BROMIDE) NOVARTIS EUROPHARM LIMITED, TRAJENTA LINAGLIPTIN BOEHRINGER INGELHEIM INTERNATIONAL GMBH TRESIBA INSULIN DEGLUDEC NOVO NORDISK A/S TROBALT RETIGABINE GLAXO GROUP LTD TYBOST COBICISTAT??? TYGACIL TIGECYCLINE PFIZER LIMITED TYSABRI NATALIZUMAB BIOGEN IDEC LTD TYVERB LAPATINIB (DITOSYLATE MONOHYDRATE) GLAXO GROUP LTD Conditional auth ULTIBRO BREEZHALER INDACATEROL (MALEATE) MCG/DO, GLYCOPYRRONIUM (BROMIDE) MCG/DO NOVARTIS EUROPHARM LIMITED VECTIBIX PANITUMUMAB MG/ML AMGEN EUROPE BV Conditional auth VEDROP TOCOPHEROL D-ALPHA (AS TOCOFERSOLAN) ORPHAN EUROPE SARL Auth under excep circumstances, VEPACEL INFLUENZA VIRUS (INACTIVATED) Q.S. BAXTER INNOVATIONS GMBH VICTRELIS BOCEPREVIR MERCK SHARP & DOHME LTD VIPDOMET ALOGLYPTIN / METFORMIN??? VIPIDIA ALOGLYPTIN??? VITEKTA Elvitegravir Gilead Sciences International Ltd VONCENTO FACTOR VIII HUMAN IU, FACTOR VON WILLEBRAND IU TEVA PHARMA BV VOTUBIA EVEROLIMUS NOVARTIS EUROPHARM LIMITED Conditional auth
6 VYNDAQEL TAFAMIDIS (MEGLUMINE) PFIZER LIMITED Auth under excep circumstances, New AS, XAGRID XAGRID SHIRE PHARMACEUTICAL CONTRACTS LTD Auth under excep circumstances XALKORI CRIZOTINIB PFIZER LIMITED, Cond Auth XARELTO RIVAROXABAN MG BAYER SCHERING PHARMA AG XGEVA DENOSUMAB AMGEN EUROPE BV New biological XIAPEX COLLAGENASE CLOSTRIDIUM HISTOLYTICUM AUXILIUM UK LIMITED XOFIGO Radium Ra 223 dichloride Bayer Pharma AG XOTERNA BREEZHALER INDACATEROL / GLYCOPYRRONIUM TEVA PHARMA BV XTANDI ENZALUTAMIDE ASTELLAS PHARMA EUROPE B.V. YELLOX BROMFENAC (SODIUM SESQUIHYDRATE) CROMA-PHARMA GMBH YERVOY IPILIMUMAB BRISTOL-MYERS SQUIBB PHARMA EEIG, YONDELIS TRABECTEDIN PHARMA MAR SA Auth under excep circumstances ZALTRAP AFLIBERCEPT SANOFI-AVENTIS GROUPE ZELBORAF VEMURAFENIB ROCHE REGISTRATION LIMITED ZINFORO CEFTAROLINE FOSAMIL (ACETIC ACID SOLVATE MONOHYDRATE) ASTRAZENECA AB ZYTIGA ABIRATERONE ACETATE JANSSEN-CILAG INTERNATIONAL NV NOTE In Red in Black in blue in grey Conditional auth commercialised / commercialisé / gecommercialiseerd not commercialised / pas commercialisé / niet gecommercialiseerd info not yet available / info non disponible / info niet beschikbaar New addition of this month / nouvelle addition de ce mois / nieuwe toevoeging van deze maand nouvelle substance active / nieuw actief bestanddeel nouveau médicament biologique / nieuwe biologische geneesmiddel Etude de sécurité post-autorisation / post-autorisatie veiligheidsstudies Autorisé sous certaines conditions / vergund onder bepaalde voorwaarden
7 Auth under excep circumstances autorisé sous circonstances exceptionnelles / vergund onder uitzonderlijke omstandigheden Product informations / informations sur les produits / produkten informaties informations sur les produits/productinformatie
AMYVID FORBETAPIR (F 18) Q.S. ELI LILLY NEDERLAND BV New AS ARZERRA OFATUMUMAB 20.00 MG/ML GLAXO GROUP LTD Conditional auth, PASS
Final Belgian list: marketing name Active substance MAH Reason on list ADASUVE LOXAPINE ALEXZA UK LTD New AS ADCETRIS BRENTUXIMAB VEDOTINE TAKEDA GLOBAL R&D CENTRE (EUROPE) LTD New AS, Cond Auth, PASS
NEISSERIA MENINGITIDES B, RECOMBINANT, COMPONENT, ADSORBED Q.S.
Final Belgian list: (Last update 07/02/2014) marketing name Active substance MAH Reason on list ADCETRIS BRENTUXIMAB VEDOTINE TAKEDA GLOBAL R&D CENTRE (EUROPE) LTD, Cond Auth, ALDURAZYME LARONIDASE GENZYME
NEISSERIA MENINGITIDES B, RECOMBINANT, COMPONENT, ADSORBED Q.S.
Final Belgian list: (Last update 13/03/2015) marketing name Active substance MAH Reason on list ABASRIA INSULINE GLARGINE ELI LILLY REGIONAL OPERATIONS GMBH New Biological ACCOFIL FILGASTRIM ACCORD HEALTHCARE
comparison of access and reimbursement environments A report benchmarking Australia s access to new medicines Edition 1
comparison of access and reimbursement environments A report benchmarking Australia s access to new medicines Edition 1 March 2015 Welcome to the first COMPARE report. This report provides information
NEISSERIA MENINGITIDES B, RECOMBINANT, COMPONENT, ADSORBED Q.S.
Final Belgian list: (Last update 07/10/2015) marketing name Active substance MAH Reason on list ABASRIA INSULINE GLARGINE ELI LILLY REGIONAL OPERATIONS GMBH New Biological ACCOFIL FILGASTRIM ACCORD HEALTHCARE
NEISSERIA MENINGITIDES B, RECOMBINANT, COMPONENT, ADSORBED Q.S.
Final Belgian list: (Last update 07/10/2015) marketing name Active substance MAH Reason on list ABASRIA INSULINE GLARGINE ELI LILLY REGIONAL OPERATIONS GMBH New Biological ACCOFIL FILGASTRIM ACCORD HEALTHCARE
13 ADDITIONS - 1 RETRAIT
Final Belgian list: (Last update 07/12/2015) marketing name Active substance MAH Reason on list Monthly modifications: +/- 13 ADDITIONS - 1 RETRAIT ABASRIA INSULINE GLARGINE ELI LILLY REGIONAL OPERATIONS
NEW DRUG APPROVALS IN ICH COUNTRIES 2004 2013 FOCUS ON 2013
24 24 24 Approval time (days) Approval time (years) NEW DRUG APPROVALS IN ICH COUNTRIES 24 FOCUS ON Median 25 th and 75 th percentile 12 1 8 6 NASs approval time by approval year 24- Median; 25 th and
PATIENT ASSISTANCE PROGRAMS
PATIENT ASSISTANCE PROGRAMS Definitions SAP Class I Class II BC Cancer Agency Health Canada Special Access Program Reimbursed for active cancer or approved treatment or approved indication only Reimbursed
Manufacturer of drug substance
Original s and Biosimilars (marketing authorizations in the EU) Date: January 2016 1) Somatropin s ORIGINAL PRODUCTS: Authorization Genentech Genotropin Somatropin Pharmacia/ Pfizer E. coli Humatrope Somatropin
Monitoring Usage in Wales of Medicines Appraised by NICE and AWMSG
Monitoring Usage in Wales of s Appraised by NICE and AWMSG October 2014 This report has been prepared by the Welsh Analytical Prescribing Support Unit (WAPSU), part of the All Wales Therapeutics and Toxicology
Outcomes of Monitoring Committee Reviews. Medicines Australia Code of Conduct
Outcomes of Monitoring Committee Reviews Medicines Australia Code of Conduct 1 Medicines Australia ABN 23 126 990 001 Level 1, 16 Napier Close Deakin ACT 2600 Phone: 02 6122 8500 Fax: 02 6122 8555 Web:
Guide. Astellas Pharma US, Inc. XTANDI Access Services SM 2015 NCCN Virtual Reimbursement Resource Room. NCCN.org/reimbursement
Astellas Pharma US, Inc. XTANDI Access Services SM 2015 NCCN Virtual Reimbursement Resource Room Guide The oncology reimbursement landscape continues to present ever-evolving challenges for clinicians
Clinical trial research agreement Agreed schedule 4 or 7 clause amendments
Clinical trial research agreement Agreed schedule 4 or 7 clause amendments Medicines Australia and Medical Technology Association of Australia templates The sponsors in the table have agreed clauses for
CHEM-E4140 Selectivity 12. Pharma Business
CHEM-E4140 Selectivity 12. Pharma Business Prof. Ari Koskinen Laboratory of Organic Chemistry C318 Pharma Business Total volume ca 1100 G$ (Shell 421G$; Walmart 486G$; Toyota 252 G$). Annually approx 25
FDA Office of Hematology and Oncology Products (OHOP) 2011 Review
FDA Office of Hematology and Oncology Products (OHOP) 2011 Review 1 OHOP 130 total employees 55 oncologists including 9 pediatric oncologists 25 PhDs in Pharmacology/Toxicology 24 Regulatory Project Managers
The Newcastle upon Tyne Hospitals NHS Foundation Trust. Handling, Segregation and Disposal of Cytostatic and Cytotoxic Waste
The Newcastle upon Tyne Hospitals NHS Foundation Trust Handling, Segregation and Disposal of Cytostatic and Cytotoxic Waste Version.: 1.1 Effective From: 20 January 2016 Expiry Date: 20 January 2019 Date
WORLD PREVIEW 2014, OUTLOOK TO 2020
WORLD PREVIEW 2014, OUTLOOK TO 2020 June 2014 Welcome to the EvaluatePharma World Preview 2014, Outlook to 2020 The seventh edition of EvaluatePharma s World Preview brings together many of our analyses
Metastatic Breast Cancer - Pipeline Review, Q1 2011
Brochure More information from http://www.researchandmarkets.com/reports/1524592/ Metastatic Breast Cancer - Pipeline Review, Q1 2011 Description: Metastatic Breast Cancer - Pipeline Review, Q1 2011 Summary
List of nationally authorised medicinal products
9 July 2015 EMA/483660/2015 Procedure Management and Committees Support Active substance: diphtheria, tetanus, pertussis (acellular, component), poliomyelitis (inactivated), haemophilus type b conjugate
Decision Matrix: Selecting a CRM Vendor in the Pharmaceutical Market (Competitor Focus)
A Datamonitor report Decision Matrix: Selecting a CRM Vendor in the Pharmaceutical Market (Competitor Focus) Published: Oct 07 Product Code: DMTC2133 Providing you with: Identifies which technology vendors
Special Authorization
Special Authorization Certain medications in the Reformulary require Special Authorization from your insurance company before your prescription is eligible for coverage. What is Special Authorization?
Multiple Sclerosis Therapeutics to 2019 - Treatment Diversification, Increasing Efficacy, and Pipeline Innovation Combine to Drive Growth
Brochure More information from http://www.researchandmarkets.com/reports/2640803/ Multiple Sclerosis Therapeutics to 2019 - Treatment Diversification, Increasing Efficacy, and Pipeline Innovation Combine
Pharma working capital performance highly variable
April 2014 Pharma working capital performance highly variable 41 Billion in Excess Working Capital We last completed this survey in 2012. We expected that there would be a broad improvement across the
6 th Proactive GCP Compliance Effective Risk- Based Approaches for Optimizing Clinical Quality
6 th Proactive GCP Compliance Effective Risk- Based Approaches for Optimizing Clinical Quality March 24-25, 2015 Wyndham Philadelphia Historic District, Philadelphia, PA www.exlevents.com/gcp Sponsors
EU Clinical Trials Register
EU Clinical Trials Register Sponsor Contact Information Abbott Laboratories Ltd Abbott House, Vanwall Business Park, Vanwall Road, Maidenhead, Berkshire SL6 4XE UK Telephone number +44 1628 644475 [email protected]
The power of creativity www.originbranding.com. Pharmaceutical Branding 2012
The power of creativity www.originbranding.com Pharmaceutical Branding 2012 We are an independent, boutique agency passionately focused on developing pharmaceutical brands. For over 15 years we have delivered
KEEPING CLINICAL TRIALS IN AUSTRALIA
OCCASIONAL PAPER SERIES KEEPING CLINICAL TRIALS IN AUSTRALIA WHY ACTION IS NEEDED NOW OCCASIONAL PAPER SERIES > Medicines Australia is producing Occasional Papers to promote a contest of ideas, thought
May 2013 Declining Medicine Use and Costs: For Better or Worse?
May 2013 Declining Medicine Use and Costs: For Better or Worse? A Review of the Use of Medicines in the United States in 2012 Introduction In 2012, both the per capita use and cost of medicines declined.
Applications for new human medicines under evaluation by the Committee for Medicinal Products for Human Use
25 April 2014 EMA/237058/2014 Procedure Management and Business Support Division Applications for new human under evaluation by the Committee for Medicinal Products for Human Use April 2014 This document
ehealthinsight Series: Online Patient Recruitment Strategies
A Datamonitor report ehealthinsight Series: Online Patient Recruitment Strategies Published: May-08 Product Code: Providing you with: Overview of benefits and drawbacks of online Analysis of online patient
Biggest Launches 2014
Biggest Launches 2014 The recent staggering performance of the biotech industry has been built around a belief that the sector s R&D productivity is on the rebound and will deliver huge investor returns
Malignant Mesothelioma - Pipeline Review, H1 2015
Brochure More information from http://www.researchandmarkets.com/reports/3308784/ Malignant Mesothelioma - Pipeline Review, H1 2015 Description: Malignant Mesothelioma - Pipeline Review, H1 2015 Summary
Pharma working capital leaves room for improvement
October 2012 Pharma working capital leaves room for improvement 50.7 Billion in Excess Working Capital Ten years ago it was not unusual to be asked why working capital mattered to a pharmaceutical company.
Product Profiles: Multiple Sclerosis - Gilenya Raises Bar for New Market Entrants
Brochure More information from http://www.researchandmarkets.com/reports/1841621/ Product Profiles: Multiple Sclerosis - Gilenya Raises Bar for New Market Entrants Description: Introduction Beginning with
Annual Press Conference 2012. Business Year 2011
Business Year 2011 Highlights of the Business Year 2011 Andreas Barner Chairman of the Board of Managing Directors Corporate Board Division Pharma Research, Development and Medicine Value through Innovation
ATC/DDD Classification
ATC/DDD Classification ATC/DDD Classification (Temporary) The following ATC codes, DDDs and alterations were agreed at the meeting of the WHO International Working Group for Drug Statistics Methodology
Listes des médicaments pour les maladies rares en Europe*
Avril 2014 Listes des médicaments pour les maladies rares en Europe* *Autorisation de mise sur le marché de la Communauté Européenne par procédure centralisée www.orpha.net Sommaire général PARTIE 1: Liste
Rx-360 An International Pharmaceutical Supply Chain Consortium
Rx-360 An International Pharmaceutical Supply Chain Consortium Overview Rx-360 and the Audit Sharing Program September 2011 Rx-360 Members (Continuously updated list at www.rx-360.org) Manufacturers (24)
BOLT Hem/Onc Thought Leader Panel #38 Cancer Immunotherapy 2014-05
Syndicated Thought Leader Insight Healthcare & Pharmaceutical Research Cancer Immunotherapy Melanoma, Non- Small Cell Lung Cancer, Renal Cell Carcinoma Thought Leader Panel #38 2014-05 Therapeutic Area:
Global Non-Small Cell Lung Cancer Therapeutics Market 2015-2019
Brochure More information from http://www.researchandmarkets.com/reports/3453273/ Global Non-Small Cell Lung Cancer Therapeutics Market 2015-2019 Description: About non-small cell lung cancer therapeutics
Lists of medicinal products for rare diseases in Europe*
October 2015 Lists of medicinal products for rare diseases in Europe* *European Community marketing authorisation under the centralised procedure www.orpha.net General Table of contents PART 1: List of
REFERENCE CODE GDHC96PIDR PUBLICATION DATE APRIL 2015 PROSTATE CANCER GLOBAL DRUG FORECAST AND MARKET ANALYSIS TO 2023
REFERENCE CODE GDHC96PIDR PUBLICATION DATE APRIL 2015 PROSTATE CANCER GLOBAL DRUG FORECAST AND MARKET ANALYSIS TO 2023 Executive Summary Prostate Cancer: Key Metrics in the 9MM, 2013 2023 2013 Epidemiology
Pain management for cancer patients Acute Ischemic Stroke. Hemophilia, Von willebrand disease & Bleeding disorders. Infectious Disease
Cigna Specialty Pharmacy Services Limited Distribution and Risk Evaluation Mitigation (RE) Drug List Last updated on 04/06/2015 Medication Brand Name Condition Actemra Rheumatroid Arthritis Acthar Seizure
Stakeholder Perspectives: Mild Cognitive Impairment and Dementia
A Datamonitor In-Depth Analysis Stakeholder Perspectives: Mild Cognitive Impairment and Dementia Aricept in Race to Pioneer Unexplored Markets Published: Aug-03 Product Code: DMHC1924 Why buy this analysis?
Review of the List of High-Cost Medicines used by the Dominican Republic s Protected Diseases Program and Planning of Purchases for 2015
Review of the List of High-Cost Medicines used by the Dominican Republic s Protected Diseases Program and Planning of Purchases for 2015 July 2014 Review of the List of High-Cost Medicines Used by the
M&A und Allianzen in Life Science Aktuelle Entwicklungen und Trends
M&A und Allianzen in Life Science Aktuelle Entwicklungen und Trends Symposium Life Science am Kapitalmarkt Frankfurt, 3. Juni 28 Global biotech industry Strong growth in most areas but Visible product
Liste des médicaments pour les maladies rares en Europe*
Janvier 2016 Liste des médicaments pour les maladies rares en Europe* *Autorisation de mise sur le marché de la Communauté Européenne par procédure centralisée www.orpha.net Sommaire général PARTIE 1:
Robert Ancuceanu for his exceptional work as he has resigned from the Committee and adopted the following opinions:
News from the EMA Activities of the PDCO During its meeting from 10-12 November 2010 the Paediatric Committee (PDCO) thanked Robert Ancuceanu for his exceptional work as he has resigned from the Committee
Listes des médicaments pour les maladies rares en Europe*
Janvier 2014 Listes des médicaments pour les maladies rares en Europe* *Autorisation de mise sur le marché de la Communauté Européenne par procédure centralisée www.orpha.net Sommaire général PARTIE 1:
Specialty Pipeline Update
CLINICAL SOLUTIONS Drug Insights > June 2014 Specialty Pipeline Update New Drug Information Eloctate (recombinant factor VIII Fc fusion protein): Biogen received FDA approval for their hemophilia A for
Biopharmaceutical Raw Materials throughout the Product Lifecycle
February 27 March 2, 2012 Hilton San Diego Bayfront San Diego, CA Monday Tuesday Programming: IBC s 17th International Process & Analytical Assay Validation IBC s 8th International Outsourcing Manufacturing
SMC Accepted Medicine Indication Formulary Decision To be used on Treatment of unresectable or metastatic, well- or everolimus (Afinitor) Novartis
SMC Accepted Medicine Indication Formulary Decision To be used on Treatment of unresectable or metastatic, well- or everolimus (Afinitor) Novartis advice moderately-differentiated neuroendocrine Pharmaceuticals
Multiple Sclerosis. Current and Future Players. GDHC1009FPR/ Published March 2013
Multiple Sclerosis Current and Future Players GDHC1009FPR/ Published March 2013 Executive Summary Moderate Growth in the Multiple Sclerosis Market is Expected from 2012 2022 GlobalData estimates the 2012
Indication: Posology: Indication: Posology:
Maklumat tambahan indikasi untuk upload pada laman web Year 2014 Products Approved For Additional Indication (DCA 275 9 Mei 2014) NO PRODUCT (ACTIVE INGREDIENT) 1. 1.1 Trajenta Duo 2.5mg/500mg Film-Coated
Applications for new human medicines under evaluation by the Committee for Medicinal Products for Human Use
23 June 206 EMA/40396/206 - corr Information Management Division Applications for new human medicines under evaluation by the Committee for Medicinal Products for Human Use June 206 This document lists
Commercial Insight Osteoarthritis and Rheumatoid Arthritis
A Datamonitor In-Depth Analysis Commercial Insight Osteoarthritis and Rheumatoid Arthritis New Growth In A Mature Market Published: Jul-03 Product Code: DMHC1891 Why buy this analysis? Target current and
Inventory of Access and Prices of Orphan Drugs across Europe:
www.eurordis.org Inventory of Access and Prices of Orphan Drugs across Europe: A Collaborative Work between National Alliances on Rare Diseases & Eurordis Yann Le Cam Chief Executive Officer, EURORDIS
Pharmaceutical Marketing Disclosures
Pharmaceutical Marketing Disclosures July 1, 2007 June 30, 2008 Report of Vermont Attorney General William H. Sorrell April 2009 Prepared by staff of the Vermont Attorney General s Office: Wendy Morgan,
Committee for Orphan Medicinal Products (COMP)
11 October 2010 EMA/COMP/586816/2010 Human Medicines Development and Evaluation Monthly report 6-7 October 2010 The Committee for Orphan Medicinal Products held its 116 th plenary meeting on 6-7 October
Verzeichnis der Arzneimittel für seltene Krankheiten in Europa*
Oktober 2014 Verzeichnis der Arzneimittel für seltene Krankheiten in Europa* *Zentrales Zulassungsverfahren der Europäischen Gemeinschaft www.orpha.net Allgemeiner Überblick des Inhaltes TEIL 1: Verzeichnis
Multiple Sclerosis Drug Discoveries - What the Future Holds
Brochure More information from http://www.researchandmarkets.com/reports/1408035/ Multiple Sclerosis Drug Discoveries - What the Future Holds Description: The recent approval in the US of Novartis' orally
Global Peptide Therapeutics Market 2014-2018
Brochure More information from http://www.researchandmarkets.com/reports/3022209/ Global Peptide Therapeutics Market 2014-2018 Description: About Peptide Therapeutics Peptides are amino acids sequences
Serialization Technology - Seidenader: Integral Solution Provider
Serialization Technology - Seidenader: Integral Solution Provider Sindusfarma August, 28th 2013 Dr. Stefan Loelkes Agenda 1 2 Your challenge Company overview 3 4 Integral solution provider Products 2 Your
Key Findings. Use this report to... The Autoimmune Market Outlook to 2013
Key Findings The global autoimmune market generated sales of $31.9bn in, an increase of 14.4% over 2006 sales. The market is forecast to grow at a CAGR of 8.1% to reach a total value of $51.0bn in 2013.
CODE FOR DISCLOSURE OF TRANSFERS OF VALUE BY PHARMACEUTICAL COMPANIES TO HEALTHCARE PROFESSIONALS AND HEALTH ORGANIZATIONS
CODE FOR DISCLOSURE OF TRANSFERS OF VALUE BY PHARMACEUTICAL COMPANIES TO HEALTHCARE PROFESSIONALS AND HEALTH ORGANIZATIONS Adopted November 2013, in force since 1 st of January 2014. INTRODUCTION The Association
The type 2 diabetes market is undergoing a paradigm
Elsevier Business Intelligence PRESCRIPTION PHARMACEUTICALS AND BIOTECHNOLOGY July 16, 2012 Founded 1939 In A Changing Diabetes Drug Market, Who Will Come Out On Top? Jessica Merrill [email protected]
Healthcare Insights. A global price management system: Bringing price management in the pharmaceu cal industry into the 21 st century By Anish Shah
Healthcare Insights A publica on for the clients of Simon-Kucher & Partners Inside This Issue What the FDA s breakthrough therapy designation means for pricing and market access How biosimilars and new
Global Pharmaceuticals Marketing Channel Reference EDITION
Global Pharmaceuticals Marketing Channel Reference EDITION 2015 ABOUT IMS HEALTH IMS Health is a leading global information and technology services company providing clients in the healthcare industry
Novel OAC s : How should we use them?
Novel OAC s : How should we use them? Jean C. Grégoire MD, FRCP(c), FACC, FACP Associate Professor, Université de Montréal, IntervenJonal Cardiologist, InsJtut de cardiologie de Montréal Disclosures Speaker
drugs in development CuraScript Specialty Pharmacy Management Guide & Trend Report
CuraScript Specialty Pharmacy Management Guide & Trend Report Drugs in Development There are currently more than 324 drugs in development for nearly 150 disease states. These potential new medications
THE ROYAL CORNWALL HOSPITALS NHS TRUST RESPONSE TO INFORMATION REQUEST. Date Request Received: 03 August 2015 FOI Ref: 947
FREEDOM OF INFORMATION ACT 2000 THE ROYAL CORNWALL HOSPITALS NHS TRUST RESPONSE TO INFORMATION REQUEST Date Request Received: 03 August 2015 FOI Ref: 947 Requested Information For the Royal Cornwall Hospitals
Orphan drugs program. Discussion paper. May 2015
Orphan drugs program Discussion paper About the Therapeutic Goods Administration (TGA) The Therapeutic Goods Administration (TGA) is part of the Australian Government Department of Health, and is responsible
Pricing & Market Access Outlook 2012 Edition
Pricing & Market Access Outlook 2012 Edition TM Pricing & Market Access Outlook 2012 Edition Acknowledgements Thank you to the following people for their contributions to this report: Authors Marc Benoff,
Medical School for Actuaries. June 12, 2013. Baltimore, Maryland
Medical School for Actuaries June 12, 2013 Baltimore, Maryland Developments in the Treatment of Conditions Treated with Specialty Mediations (Cancer, MS, RA, Hemophilia) Mark S. Matusik, PharmD Developments
HIV 1. A reference guide for prescription HIV-1 medications
HIV 1 A reference guide for prescription HIV-1 medications Several different kinds of antiretroviral drugs are currently used to treat HIV-1 infection. These medicines are the ones most commonly used in
Small-Cell Lung Cancer Global Clinical Trials Review, H2, 2015
Brochure More information from http://www.researchandmarkets.com/reports/3398017/ Small-Cell Lung Cancer Global Clinical Trials Review, H2, 2015 Description: Small-Cell Lung Cancer Global Clinical Trials
Drugs Not Approved By the Scottish Medicines Consortium
December 2014 Vol. 11 No. 3 Outlined below in this newsletter are the recommendations for new drugs which have been through the locally agreed process (see appendix I). Please remember that the ADTC advises
PHARMACEUTICAL INDUSTRY PROFILE
PHARMACEUTICAL INDUSTRY PROFILE I. INDUSTRY BACKGROUND A. Industry Definition The U.S. pharmaceutical industry is defined by the Census Bureau as companies engaged in researching, developing, manufacturing,
Hydration, IV Infusions, Injections and Vaccine Charge Process
There are a number of items to be considered when billing for the Nursing service to perform drug therapy, the charge process is divided into three specific groups of codes and processes. 1. Hydration
Growth in revenue from MS drugs has been driven largely by price increases over the last several years.
March 4, 2013 Ben Weintraub, PhD Are Injectable MS Drugs Finished? Market Ready for Tecfidera Companies: Biogen (BIIB) Sanofi (SNY) Teva (TEVA) Novartis (NVS) Merck Serono Bayer Schering Products: Tecfidera
Elenchi dei prodotti medicinali per le malattie rare in Europa*
Luglio 2015 Elenchi dei prodotti medicinali per le malattie rare in Europa* *Autorizzazione all immissione in commercio della Comunità Europea nell ambito della procedura centralizzata www.orpha.net Indice
PAYS D'ORIGINE NOM DOSAGE FORME NR ST LABORATOIRE A-CNOTREN 20MG 30 SOFT CAPSULES 218180/09 * GAP S.A FOR PHARMATHEN S.A GRECE ACUVAIL 0.
NOM DOSAGE FORME NR ST LABORATOIRE PAYS D'ORIGINE A-CNOTREN 20MG 30 SOFT CAPSULES 218180/09 * GAP S.A FOR PHARMATHEN S.A GRECE ACUVAIL 0.45% 0.4ML X 30 SINGLE USE VIALS 097674/11 ALLERGAN SALES LLC USA
Fourth Quarter 2014 Provider Connection
Healthy Michigan Plan Health Risk Assessments Do you need clarification or information related to the completion of the Healthy Michigan Plan (HMP) member Health Risk Assessment (HRA) form? Resources and
National Cancer Drugs Fund List (Updated 13 February 2014)
National Cancer Drugs Fund List (Updated 13 February 2014) DRUG Abiraterone Aflibercept Axitinib Bendamustine NCDF APPROVED CRITERIA The treatment of metastatic castration resistant prostate cancer where
Malignant Pleural Mesothelioma - Pipeline Review, H2 2014
Brochure More information from http://www.researchandmarkets.com/reports/2904677/ Malignant Pleural Mesothelioma - Pipeline Review, H2 2014 Description: Malignant Pleural Mesothelioma - Pipeline Review,
Elenchi dei prodotti medicinali per le malattie rare in Europa
Gennaio 2014 Elenchi dei prodotti medicinali per le malattie rare in Europa *Autorizzazione all immissione in commercio della Comunità Europea nell ambito della procedura centralizzata www.orpha.net Indice
I Quaderni di Orphanet
I Quaderni di Orphanet Collezione Farmaci Orfani Luglio 2013 Elenchi dei prodotti medicinali per le malattie rare in Europa *Autorizzazione all immissione in commercio della Comunità Europea nell ambito
December 17, 2014 HOW PHARMA MARKETERS FIND AND SELECT DIGITAL MARKETING AGENCIES
December 17, 2014 HOW PHARMA MARKETERS FIND AND SELECT DIGITAL MARKETING AGENCIES by Dennis van Rooij with Tim van Tongeren EXECUTIVE SUMMARY More than half of pharma marketers don t or can t leverage
Listados de medicamentos para enfermedades raras en Europa*
Octubre 2015 Listados de medicamentos para enfermedades raras en Europa* *Autorización de comercialización de la Comunidad Europea mediante el procedimiento centralizado www.orpha.net Índice general PARTE
STAT Bulletin. Drug Therapy Guideline Updates. May 11, 2012 Volume: 18 Issue: 12
STAT Bulletin May 11, 2012 Volume: 18 Issue: 12 To: All primary care physicians and specialists Contracts Affected: All Lines of Business Drug Therapy Guideline Updates Why you re receiving this Stat What
Commercial Perspectives: Multiple Sclerosis
A Datamonitor Report Commercial Perspectives: Multiple Sclerosis How to Find Opportunities in an Unremitting Market Published: Jun-04 Product Code: Providing you with: In-depth profiles of current market-leading
Marketing authorisations granted in March 2016
PL 10321/0204 01/03/2016 RESOLUTION CHEMICALS LIMITED HYDROCORTISONE 10 MG TABLETS HYDROCORTISONE 10.00 MILLIGRAMMES POM PL 10321/0205 01/03/2016 RESOLUTION CHEMICALS LIMITED HYDROCORTISONE 20 MG TABLETS
Package Leaflet: Information for the user
Package Leaflet: Information for the user ZOSTAVAX Powder and solvent for suspension for injection in a pre-filled syringe shingles (herpes zoster) vaccine (live) Read all of this leaflet carefully before